R428 is perhaps the best studied inhibitor, and its role in NSCLC is very encouraging with clinical response achieved when paired with chemotherapy, EGFR TKI, or immune checkpoint inhibitors [69]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.